XFOR X4 Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XFOR

Price (delayed)

$1.15

Market cap

$193.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.57

Enterprise value

$152.19M

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 ...

Highlights
The EPS has soared by 63% year-on-year and by 19% since the previous quarter
X4 Pharmaceuticals's net income has increased by 9% from the previous quarter but it has decreased by 8% YoY
The debt has soared by 52% YoY
The equity has contracted by 31% YoY and by 24% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.x4pharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of XFOR
Market
Shares outstanding
167.94M
Market cap
$193.13M
Enterprise value
$152.19M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$95.31M
EBITDA
-$93.32M
Free cash flow
-$96.57M
Per share
EPS
-$0.57
Free cash flow per share
-$0.54
Book value per share
$0.31
Revenue per share
$0
TBVPS
$0.73
Balance sheet
Total assets
$147.26M
Total liabilities
$96.16M
Debt
$58.28M
Equity
$51.1M
Working capital
$99.21M
Liquidity
Debt to equity
1.14
Current ratio
5.34
Quick ratio
5.02
Net debt/EBITDA
0.44
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-65.4%
Return on equity
-170.1%
Return on invested capital
-202.1%
Return on capital employed
-76.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XFOR stock price

How has the X4 Pharmaceuticals stock price performed over time
Intraday
6.48%
1 week
-1.71%
1 month
-21.77%
1 year
-22.3%
YTD
37.15%
QTD
-17.27%

Financial performance

How have X4 Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$107.52M
Net income
-$101.17M
Gross margin
N/A
Net margin
N/A
XFOR's operating income is down by 23% year-on-year
X4 Pharmaceuticals's net income has increased by 9% from the previous quarter but it has decreased by 8% YoY

Growth

What is X4 Pharmaceuticals's growth rate over time

Valuation

What is X4 Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 63% year-on-year and by 19% since the previous quarter
The stock's price to book (P/B) is 121% more than its 5-year quarterly average of 1.7 and 39% more than its last 4 quarters average of 2.7
The equity has contracted by 31% YoY and by 24% from the previous quarter

Efficiency

How efficient is X4 Pharmaceuticals business performance
XFOR's return on invested capital is up by 26% year-on-year and by 26% since the previous quarter
XFOR's return on assets is up by 24% year-on-year and by 8% since the previous quarter
The company's return on equity rose by 4.9% YoY

Dividends

What is XFOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XFOR.

Financial health

How did X4 Pharmaceuticals financials performed over time
XFOR's total assets is 53% greater than its total liabilities
XFOR's total liabilities is up by 18% year-on-year but it is down by 9% since the previous quarter
XFOR's total assets is down by 15% since the previous quarter and by 5% year-on-year
The debt is 14% more than the equity
X4 Pharmaceuticals's debt to equity has soared by 119% YoY and by 33% from the previous quarter
The debt has soared by 52% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.